ClinConnect ClinConnect Logo
Search / Trial NCT00000931

HIV Prevention Counseling for Men Who Have Sex With Men

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of March 21, 2025

Completed

Keywords

Homosexuality, Male Risk Taking Behavior Therapy Hiv Seronegativity

ClinConnect Summary

The intervention being evaluated in this trial is based on the extensive literature on behavioral approaches to risk reduction in MSM. These reviews recommend an intervention that, unlike the current standard HIV pre-test and post-test risk-reduction counseling, is tailored to an individual's unique problems and needs, lifestyle, and situations that contribute to high-risk behavior. Furthermore, there is a need for HIV-prevention intervention trials using biological endpoints (e.g., HIV seroconversion) in addition to behavioral change indices.

Participants are randomly assigned to receive ...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria
  • Participants may be eligible for this study if they:
  • Are an HIV-negative man who has had anal sex with another man in the 12 months prior to study entry.
  • Are able to attend all scheduled study visits.
  • Are able to provide information for locator purposes (address, phone number, etc.).
  • Are at least 18 years old.
  • Exclusion Criteria
  • Participants will not be eligible for this study if they:
  • Have been in a monogamous relationship for 2 years or more with an HIV-negative man. (Monogamous is defined as a relationship in which the members of the couple engage in sexual activities with only each other.)
  • Have an obvious mental disorder or any another condition that would prevent them from completing the study.
  • Are currently enrolled in any Phase III HIV vaccine trial, including the AIDSVAX Phase III trial sponsored by VaxGen, Inc.
  • Are currently enrolled in HIVNET Protocol 014.
  • Were enrolled in the HIVNET 015 Pilot Study.

Trial Officials

Chesney M, Coates T

Study Chair

Koblin B

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Seattle, Washington, United States

Bronx, New York, United States

San Francisco, California, United States

Denver, Colorado, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

People applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials